Cultivating an understanding of the VC investment landscape of US-based biotech & pharma startups.
- Over the last few decades, the biotechnology & pharmaceuticals (biotech & pharma) industry has seen a shift from drug development through internal R&D efforts at large-cap public incumbents to an M&A-based model.
- The drug development lifecycle, characterized by clear intermittent milestones and long-payback periods with high upside, makes biotech startups uniquely positioned to receive illiquid VC investment.
- As VC biotech investing has evolved, three distinct models have emerged for commercializing new technologies.
- Biotech startups take a different funding trajectory than most VC- backed startups, raising larger sums more quickly.
report here https://files.pitchbook.com/website/files/pdf/PitchBook_Q3_2020_Analyst_Note_Betting_on_Biotech.pdf